<?xml version="1.0" encoding="UTF-8"?>
<p>The immunogenicity, efficacy, or effectiveness of LAIVs in comparison with IIVs has been analyzed in a number of studies.
 <xref rid="irv12664-bib-0050" ref-type="ref">50</xref>, 
 <xref rid="irv12664-bib-0051" ref-type="ref">51</xref>, 
 <xref rid="irv12664-bib-0052" ref-type="ref">52</xref>, 
 <xref rid="irv12664-bib-0053" ref-type="ref">53</xref>, 
 <xref rid="irv12664-bib-0054" ref-type="ref">54</xref> A meta‚Äêanalysis of a number of investigations has shown that the LAIV has been less effective than IIV in general.
 <xref rid="irv12664-bib-0055" ref-type="ref">55</xref> However, individual studies with respect to mismatched vaccine strains or in children with underlying diseases such as asthma have shown a higher efficiency in comparison to IIV, for example, with respect to a circulating variant (A/Sydney/H3N2) not present in the vaccine composition with an efficacy of 86% against this mismatched circulating strain
 <xref rid="irv12664-bib-0051" ref-type="ref">51</xref> or in children affected by asthma
 <xref rid="irv12664-bib-0053" ref-type="ref">53</xref> or recurrent respiratory tract infections.
 <xref rid="irv12664-bib-0052" ref-type="ref">52</xref>
</p>
